Medicines for pediatric oncology: Can we overcome the failure to deliver?

Expert Review of Clinical Pharmacology

Volumn 5, Issue 5, 2012, Pages 493-495

  Saint Raymond, Agnes ^a   Herold, Ralf ^a  

^a EUROPEAN MEDICINES AGENCY   (United Kingdom)

Author keywords

child; development; medicines; oncology; regulation

Indexed keywords

ANTINEOPLASTIC AGENT;

CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CHILDHOOD CANCER; DRUG INDUSTRY; DRUG MARKETING; GENE MUTATION; GLIOMA; HEALTH CARE DISPARITY; HUMAN; NEUROBLASTOMA; REVIEW;

ADOLESCENT; AGE FACTORS; ANTINEOPLASTIC AGENTS; CHILD; CHILD, PRESCHOOL; HUMANS; INFANT; NEOPLASMS; PEDIATRICS;

EID: 84868585646     PISSN: 17512433     EISSN: 17512441     Source Type: Journal    
DOI: 10.1586/ecp.12.51     Document Type: Review

References (3)

1. Pritchard-Jones K, Kaatsch P, Steliarova-Foucher E, Stiller CA, Coebergh JW. Cancer in children and adolescents in Europe: developments over 20 years and future challenges. Eur. J. Cancer 42(13), 2183-2190 (2006).
2. Vassal G. Will children with cancer benefit from the new European Paediatric Medicines Regulation? Eur. J. Cancer 45(9), 1535-1546 (2009).
3. Smith MA, Seibel NL, Altekruse SF et al. Outcomes for children and adolescents with cancer: challenges for the twenty-first century. J. Clin. Oncol. 28(15), 2625-2634 (2010).